Moberg Sells Consumer Health Portfolio To Pay For Rx Research Focus
Executive Summary
Moberg had been expanding its OTC portfolio while also continuing trials for Rx ingredients including its MOB-015 formulation of terbinafine indicated for fingernail and toenail fungus. But $155m agreement with two investment groups will complete Moberg's divestment of consumer health brands.
You may also be interested in...
Moberg strikes Africa deal
Sweden’s Moberg Pharma is to launch its Emtrix fungal nail product across the Middle East and Africa after signing an agreement with Mundipharma.
Divestments hurt Moberg
Offloading a number of ‘non-core’ brands left turnover at Moberg Pharma down by 12% to SEK91.5 million (€8.9 million) in the first-quarter of 2018.
Moberg Adds DermoPlast Line With Bondholders' Blessing For More
Moberg says sales of DermoPlast sprays were $12m in the 12 months through September and its purchase price is around 8.9 times the estimated EBITDA for the brand during the period.